Expertise in
17
conditions

Jose L. Calleja

Majadahonda, MD, ES 
Expertise in
17
conditions
Majadahonda, MD, ES 
OverviewLocationsClinical Research

Overview

Jose Calleja practices in Majadahonda, Spain. Mr. Calleja is highly rated in 17 conditions, according to our data. His top areas of expertise are Hepatitis C, Hepatitis, Portal Hypertension, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 205 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Majadahonda, MD, Spain
Other Locations
Madrid, MD, Spain
Spain
Barcelona, CT 08036, Spain
Pilar, MD 28222, Spain
Alcorcon, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II triAl of Cabozantinib for hepaTocellular carcInoma Patients intOlerant to Sorafenib Treatment or First Line Treatment Different to sorafeNib. (ACTION Trial)
A Phase II triAl of Cabozantinib for hepaTocellular carcInoma Patients intOlerant to Sorafenib Treatment or First Line Treatment Different to sorafeNib. (ACTION Trial)
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.
A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug, Biological
Study Drugs: MBK-01, Dificlir
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
The GOING Study: Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma Progressing Under Sorafenib or After Discontinuation of Atezolizumab Plus Bevacizumab
The GOING Study: Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma Progressing Under Sorafenib or After Discontinuation of Atezolizumab Plus Bevacizumab
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Regorafenib, Nivolumab
Study Phase: Phase 1/Phase 2
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase II, Single-arm, Open-label Study to Characterise the Effect on Portal Pressure, the Effect on Renal Function and the Pharmacokinetic Profile of N-003 in Patients With Decompensated Cirrhosis
A Phase II, Single-arm, Open-label Study to Characterise the Effect on Portal Pressure, the Effect on Renal Function and the Pharmacokinetic Profile of N-003 in Patients With Decompensated Cirrhosis
Enrollment Status: Terminated
Publish Date: February 26, 2021
Intervention Type: Drug
Study Phase: Phase 2
Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension
Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension
Enrollment Status: Completed
Publish Date: August 22, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

205 Total Publications

Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD.
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: September 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Calleja's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile